Tag Archives: advaxis

July, 2018

January, 2018

March, 2017

February, 2017

August, 2016

  • 2 August

    Amgen and Advaxis Enter Cancer Immunotherapies Collaboration

    THOUSAND OAKS, Calif. and PRINCETON, N.J., Aug. 2, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) today announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient’s immune system to respond against the unique …

July, 2016

December, 2015

  • 16 December

    FDA Lifts IND Clinical Hold for Three of Advaxis’ Product Candidates

    PRINCETON, N.J., Dec. 16, 2015 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on all of the company’s Investigational New Drug (IND) applications for its three product candidates: axalimogene filolisbac …

February, 2015

  • 11 February

    Advaxis and Incyte Strike Cancer Immunotherapy Deal

    Advaxis, Inc. has signed a deal with Incyte Corporation to evaluate the combination of the companies’ investigational cancer immunotherapies. The companies announced that they have entered into a clinical trial collaboration agreement to study the combination of Advaxis’ Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte’s oral indoleamine 2,3-dioxygenase 1 (IDO1) …